Creating targeted treatments to generate immune responses against HIV
Official title: Developing and evaluating cell-specific lentivectors capable of selective in vivo generation of anti-HIV T cells to cure HIV
Funded at Albert Einstein College of Medicine · NIH-11122349 · Data updated 2026-11-12
This study is testing a new injectable treatment that helps your immune system fight HIV by creating special T cells that can target and eliminate the virus, with the hope of giving people living with HIV a chance for lasting health without needing to take daily medications.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project start | June 20, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $717,317 |
| NIH project number | 5R01AI174275-02 |
| Project ID | NIH-11122349 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are seeking alternatives to lifelong antiretroviral therapy.
✕Less likely to help
Patients who are not living with HIV or those who have advanced AIDS may not benefit from this research.
What this research studies
This research focuses on developing a new injectable treatment that uses cell-specific lentiviral vectors to generate T cells capable of fighting HIV. By engineering these T cells to express anti-HIV receptors and antibodies, the goal is to establish a strong and lasting immune response that can eliminate HIV-infected cells. This innovative approach aims to provide people living with HIV the potential for sustained remission without the need for ongoing antiretroviral therapy. The research includes preclinical studies that have shown promising safety and efficacy results, leading to FDA-approved clinical trials.
Why it matters
Potential benefit: If successful, this research could lead to a functional cure for HIV, allowing patients to maintain remission without continuous medication.
How similar studies have gone: Other research has shown success with similar CAR-T cell therapies in treating various cancers, indicating potential for this novel approach in HIV treatment.
Where this research is happening
-
Albert Einstein College of Medicine
Bronx, United States Active
Researchers
- Principal investigator: Goldstein, Harris — Albert Einstein College of Medicine
- Study coordinator: Goldstein, Harris
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.